BCLI: Brainstorm Takes Major Leap Forward In Battle vs. ALS
Zacks Small Cap Research
By Zacks Small Cap Research 18 minutes ago
go adam F tweet this morning
DO THE DD - CEO VERY BULLISH
October 7, 2014
BrainStorm Cell Therapeutics Inc. October 7, 2014 7:07 AM
"We are pleased that the FDA has granted Fast Track status for NurOwn™ as this will allow us greater and more frequent dialogue with the Agency as we continue the development of this ground-breaking cell therapy for the treatment of ALS," said Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm."Weexpect Fast Track designation, which recognizes the potential of NurOwn™ as to address an unmet medical need in ALS, to help speed and improve our development program."